TITLE

Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy

AUTHOR(S)
Nilssen, D E; O ØKteclalen
PUB. DATE
April 2004
SOURCE
Gut;Apr2004, Vol. 53 Issue 4, p487
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: It is well documented that highly active antiretroviral therapy (HAART) restores systemic immunity to human immunodeficiency virus (HIV) but the effect of this treatment on the mucosal immune system is less clear. Aims: Because future preventive or therapeutic vaccines against HIV may be administered by the mucosal route, we wished to evaluate the effect of HAART on the activation level and homeostasis of the intestinal B cell system. Patients and methods: Duodenal biopsy specimens were collected consecutively from infection prone HIV positive adults (n=31), mostly with advanced AIDS. In situ two color immunofluorescence staining was performed to quantify mucosal immunoglobulin (Ig) class and subclass producing immunocytes (plasmablasts and plasma cells). Results: HIV positive patients had, on average, duodenal proportions of IgA (74.6%), IgM (19.5%), and IgG (3.4%) immunocytes similar to median values recorded in 11 HIV seronegative healthy controls but the total immunocyte number per mucosal section length unit (500 i.xm) was significantly increased in patients (median 175 v 120 cells/unit; p<0.008), mainly comprised of IgA (p<0.02) and IgGl (median 81.8% of total IgG; p<0.02) isotypes. Patients receiving a successful HAART regimen tended to normalise their IgGl proportion and showed significantly lower total duodenal lgA immunocyte number than those receiving no or insufficient antiretroviral treatment (p < 0.005). Conclusion: Our study demonstrated that advanced AIDS patients hyperactivate their intestinal B cell system. HAART could significantly reverse this perturbation, suggesting restored ability of the mucosal immune system to control intestinal infections.
ACCESSION #
13120612

 

Related Articles

  • New HIV vaccine approach targets desirable immune cells.  // Biomedical Market Newsletter;9/12/2011, Vol. 21, p216 

    The article reports on a study which has identified that an altered form of HIV outer coating can be used for vaccine design in the U.S. It notes that an enhanced immune response can be created by the binding of immature B cell receptors to envelope proteins. It mentions that stages of pathway...

  • Maintenance of HIV-Specific Memory B-Cell Responses in Elite Controllers Despite Low Viral Burdens. Buckner, Clarisa M.; Kardava, Lela; Xiaozhen Zhang; Gittens, Kathleen; Justement, J. Shawn; Kovacs, Colin; McDermott, Adrian B.; Yuxing Li; Sajadi, Mohammad M.; Tae-Wook Chun; Fauci, Anthony S.; Moir, Susan; Zhang, Xiaozhen; Li, Yuxing; Chun, Tae-Wook // Journal of Infectious Diseases;8/1/2016, Vol. 214 Issue 3, p390 

    Human immunodeficiency virus (HIV)-specific B-cell responses in infected individuals are maintained by active HIV replication. Suppression of viremia by antiretroviral therapy (ART) leads to quantitative and qualitative changes that remain unclear. Accordingly, B-cell responses were investigated...

  • Challenges in HIV vaccine research for treatment and prevention. Ensoli, Barbara; Cafaro, Aurelio; Monini, Paolo; Marcotullio, Simone; Ensoli, Fabrizio // Frontiers in Immunology;Sep2014, Vol. 5, p1 

    Many attempts have been made or are ongoing for HIV prevention and HIV cure. Many successes are in the list, particularly for HIV drugs, recently proposed also for prevention. However, no eradication of infection has been achieved so far with any drug. Further, a residual immune dysregulation...

  • New Institute to Focus on AIDS Vaccine.  // Clinical Infectious Diseases;12/1/2008, Vol. 47 Issue 11, piii 

    The article reports on the proposed construction of a new $30 million AIDS vaccine research center at the nonprofit Scripps Research Institute in La Jolla, San Diego, California. It says that the new facility, a joint venture by Scripps and the International AIDS Vaccine Initiative, will be...

  • Antibodies. Farndon, John // Human Body;2003, p48 

    Antibodies are tiny proteins that make germs vulnerable to attack by white blood cells called phagocytes. They are produced from white blood cells derived from B lymphocytes. The body is armed from birth with antibodies for germs it had never met. Autoimmune diseases are ones in which the...

  • B-lymphocyte. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p113 

    An encyclopedia entry for "B-lymphocyte" is presented. It is a type of white blood cell that is also referred to as a B-cell. They play a vital role in the immune system by producing antibodies to find and destroy harmful microorganisms.

  • Salk HIV Vaccine Trials Begin in Philadelphia. Brownworth, Victoria A. // Advocate;1/1/91, Issue 567, p45 

    Reports on the first clinical trials for the immunogen HIV vaccine in Philadelphia, Pennsylvania. Developer of the immunogen vaccine; Restoration of immune system to a viable level in the very early stages of HIV disease; People who are involved in the trial.

  • Mayo Clinic Researchers Restore Lost Immunity; Possible Breakthrough for AIDS.  // Ascribe Newswire: Medicine;4/20/2004, p74 

    The research team, led by Mayo Clinic immunologists Marilia Cascalho, and Jeffrey Platt, reported in this month's Journal of Immunology that B cells, the lymphocytes that produce antibodies, help to generate T cells, the lymphocytes that fight viruses and tumors. Previously, it was thought that...

  • Mayo Clinic Researchers Restore Lost Immunity; Possible Breakthrough for AIDS.  // Ascribe Newswire: Medicine;4/19/2004, p71 

    Mayo Clinic researchers have found a way to revive immunity in mice that have abnormal or deficient immune systems. The discovery may lead to a means of restoring immunity to individuals with immunodeficiency diseases such as AIDS and cancer. Also, because the research involves an existing...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics